Early impairment of mucosal immunoglobulin A (IgA)-related immunity was associated with the later development of bronchiolitis obliterans syndrome (BOS) in lung transplant recipients; decreased ...

HOUSTON -- A novel self-administered shot that inhibits two key immunoregulatory cytokines reduced proteinuria in patients with IgA nephropathy, interim findings from the phase III ORIGIN 3 trial ...

COVID-19 mRNA vaccines stimulated mucosal immunity in people previously infected with SARS-CoV-2, but generated only a tiny amount of immunity in people who had never been infected, according to a ...

Sibeprenlimab is approved for IgAN treatment, showing a 51.2% reduction in proteinuria in the VISIONARY trial. Administered subcutaneously every four weeks, it inhibits APRIL to reduce IgA levels.